Evidence map›Paper›PMID 28506256›Full record

ArticleBMC biotechnology2017

AAV vector distribution in the mouse respiratory tract following four different methods of administration.

Lisa A Santry, Joelle C Ingrao, Darrick L Yu, Jondavid G de Jong, Laura P van Lieshout, Geoffrey A Wood, Sarah K Wootton

Open access · goldAbstract read
In one paragraph

Article in BMC biotechnology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 54 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. A promoterless AAV6.2FF-based lung gene editing platform for the correction of surfactant protein B deficiency.Molecular therapy : the journal of the American Society of Gene Therapy · 2023
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Lisa A SantryDepartment of Pathobiology, University of Guelph, Guelph, Ontario, N1G 2W1, Canada.
Joelle C IngraoDepartment of Pathobiology, University of Guelph, Guelph, Ontario, N1G 2W1, Canada.
Darrick L YuDepartment of Pathobiology, University of Guelph, Guelph, Ontario, N1G 2W1, Canada.
Jondavid G de JongDepartment of Pathobiology, University of Guelph, Guelph, Ontario, N1G 2W1, Canada.
Laura P van LieshoutDepartment of Pathobiology, University of Guelph, Guelph, Ontario, N1G 2W1, Canada.
Geoffrey A WoodDepartment of Pathobiology, University of Guelph, Guelph, Ontario, N1G 2W1, Canada.
Sarah K WoottonDepartment of Pathobiology, University of Guelph, Guelph, Ontario, N1G 2W1, Canada. kwootton@uoguelph.ca.
University of Guelph · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTargeted delivery of gene therapy vectors to the mouse respiratory tract is often performed via intranasal or intratracheal administration; however, there can be a great deal of variability between these methods, which could potentially influence experimental results. Improving the accuracy and precision of lung delivery will not only reduce the number of animals required to detect statistically significant differences, but may reduce the variability of studies from different laboratories.

resultsHere we evaluated three different methods of adeno-associated virus (AAV) vector administration to the respiratory tract in mice (intranasal, intubation, and intratracheal injection) and discuss the advantages, challenges, and shortcomings of each. We also present a modified-intranasal delivery technique that is superior to passive administration of vector into the nares of anesthetized supine animals. Transgene expression was consistently visible in the nasal cavity, trachea, and proximal to middle aspect of all lung lobes for all four methods, whereas transgene expression was consistently observed in the most distal aspect of lung lobes only with the intubation and intratracheal injection techniques. AAV vector genome copy numbers in the lung were approximately four-fold lower in mice that received vector via intranasal administration in comparison to the other three methods of vector delivery. The modified intranasal, intubation and intratracheal injection methods of vector administration did not yield statistical differences in AAV vector genome copy numbers in the lung. With regard to reproducibility of vector distribution within and between animals, the modified-intranasal technique was superior.

conclusionOur results show that mode of AAV vector administration to the murine respiratory tract should be selected based on desired target site and skill of the researcher, and that appropriate technique selection may greatly influence experimental outcomes.

Indexed as

Administration, IntranasalAnimalsDependovirusGene DosageGenetic VectorsIntubation, IntratrachealLungMaleMiceMice, Inbred C57BLRespiratory SystemAdeno-associated virusIntranasalIntratrachealIntubationRespiratory epitheliumRespiratory tractTransgene expressionVector instillation

Identifiers

PMID28506256
PMCPMC5433059
OpenAlexW2616358787

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.